Drug-delivery systems of phytochemicals as therapeutic strategies in cancer therapy
3 authors - Paperback
£134.00
Dr. Akhileshwar Kumar Srivastava works as a Research Associate (ICMR) in CSIR-Central Food Technological Research Institute, Mysore, India. In his eight years of research, he has published more than 16 research articles and book chapters in international and national journals of repute. His research specialization is primarily in the area of pharmacognosy with genetics, metabolomics, bioinformatics, and molecular biology-associated targeting cancer diseases. In addition, he has studied at Augusta University (formerly, Georgia Regents University) in Augusta, GA, United States on a J-1 Exchange Scholar Visa and at Ben-Gurion University, Israel. He is also a life member fellow in Indian Science Congress and Agriculture, Nutrition and Health Academy, United Kingdom. Dr. Dhruv Kumar is a Senior Associate Professor at School of Health Sciences and Technology, UPES University, Dehradun, India and his current research is focused on autophagy, cancer cell metabolism, tumour microenvironment, exosomes, mutational heterogeneity, cancer prevention, drug designing, NGS and COVID-19. After completion of B.Sc. in Chemistry from Banaras Hindu University (BHU) and M.Sc. in Bioinformatics from University of Allahabad, India, he has completed his Ph.D. in Cellular, Molecular and Industrial Biology from the University of Bologna (UNIBO), under highly prestigious fellowship, Indo-Italian Government fellowship. After his Ph.D., he obtained Postdoctoral training at the University of Kansas Medical Center, USA. During his Postdoctoral training, he worked towards understanding the molecular mechanism(s) of autophagy regulation and apoptosis in cancer stem cells (prostate, pancreatic and breast), focusing on the metabolic cross-talk between the tumour microenvironment (cancer associated fibroblast (CAF)) and head and neck squamous cell carcinoma (HNSCC) via HGF/c-MET and bFGF/FGFR signalling pathways. He has also worked on structure based drug designing for several cancers, COVID-19, mutational heterogeneity in cancer. Currently, his lab is focusing on metabolic heterogeneity in solid tumours and structure based drug designing for cancer and COVID-19. He has published more than 100 research articles, reviews and book chapters in reputed journals. Dr. Divya Singh is presently working as a scientist in Central Sericultural Research and Training Institute, Mysore, India. Her research specialization is primarily in genetics, proteomics, metabolomics, toxicology, bioinformatics, and molecular biological evaluation in various in vivo and in vitro plant models to elucidate the physiological changes and evaluate the DNA damage potency. She has published more than 10 research articles including book chapters. In addition, she is also a life member fellow of Indian Science Congress. Dr. Rajesh Kumar Singh is currently working as a Research Associate in Banaras Hindu University. His research focus is pharmacognosy, reverse pharmacology, drug design and discovery, extraction & isolation of natural products, cell culture, and handling of different rodents. He has published several research articles in reputable journals over the course of his career. At present, he is involved in developing an Indian origin cell line and screening drugs of natural origin for the treatment of gallbladder cancer.